Minapharm Pharmaceuticals (CAI:MIPH) ROCE %: 9.84% (As of Dec. 2025)


CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£698.08
GF Value E£362.13
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals ROCE %?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 ROCE % is 9.84% as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.13 (Significantly Overvalued). The stock has 10 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Minapharm Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was 9.84%.

Minapharm Pharmaceuticals  (CAI:MIPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Minapharm Pharmaceuticals ROCE % Related Terms

Minapharm Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals ROCE % Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
27.41 27.23 6.07 13.87 12.22

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.52 12.21 16.55 9.45 9.84
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals ROCE % Calculation

Minapharm Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=962.629/( ( (12003.296 - 4586.786) + (13148.14 - 4807.024) )/ 2 )
=962.629/( (7416.51+8341.116)/ 2 )
=962.629/7878.813
=12.22 %

Minapharm Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=848.556/( ( (13379.113 - 4474.621) + (13148.14 - 4807.024) )/ 2 )
=848.556/( ( 8904.492 + 8341.116 )/ 2 )
=848.556/8622.804
=9.84 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.84% mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a ROCE % of 9.84% as of Dec. 2025.
Is Minapharm Pharmaceuticals' ROCE % too high?
Minapharm Pharmaceuticals' current ROCE % is 9.84%. The Drug Manufacturers industry median ROCE % is 7.04. Minapharm Pharmaceuticals' value of 9.84% is 39.8% above this industry median. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' ROCE % compare to ZTS and UTHR?
Minapharm Pharmaceuticals' ROCE % of 9.84% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Minapharm Pharmaceuticals' value of 9.84% is 39.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current ROCE % of 9.84% is 39.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current ROCE % is 9.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.13, compared to a current price of E£698.08 — trading 92.8% above its estimated fair value. The current ROCE % is 9.84% and 39.8% above the Drug Manufacturers industry median of 7.04. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current ROCE % is 9.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.8% above its estimated GF Value™ of E£362.13. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • ROCE %: 9.84%
  • GF Value™: E£362.13 vs. price of E£698.08 (92.8% above fair value)
  • GF Score™: 41/100 with 10 warning signs
  • Industry Position: 39.8% above the Drug Manufacturers median

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08
Price
E£362.13
GF Value